.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

LASTACAFT Drug Profile

« Back to Dashboard
Lastacaft is a drug marketed by Allergan and is included in one NDA. It is available from three suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-seven patent family members in forty-one countries.

The generic ingredient in LASTACAFT is alcaftadine. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the alcaftadine profile page.

Summary for Tradename: LASTACAFT

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list3

Clinical Trials for: LASTACAFT

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 2010RXYes8,664,215<disabled> <disabled>
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 2010RXYes5,468,743<disabled>YY <disabled>
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 2010RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LASTACAFT

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan
LASTACAFT
alcaftadine
SOLUTION/DROPS;OPHTHALMIC022134-001Jul 28, 20105,468,743<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LASTACAFT

Drugname Dosage Strength RLD Submissiondate
alcaftadineOphthalmic Solution0.25%Lastacaft7/30/2014

International Patent Family for Tradename: LASTACAFT

Country Document Number Estimated Expiration
Taiwan218381<disabled in preview>
European Patent Office0588858<disabled in preview>
Canada2648115<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc